Medicom Oncology Clinical Pearls Podcasts
Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:08:26
- Mas informaciones
Informações:
Sinopsis
Dr. Eytan Stein provides a brief update on phase 1 arms of a trial studying the effectiveness of enasidenib in patients with relapsed and refractory AML and an IDH2 mutation.
